Bank of America started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Free Report) in a research report sent to investors on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.
A number of other equities research analysts have also recently issued reports on KMTS. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued a "buy" rating and a $28.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Kestra Medical Technologies in a research report on Monday. They set a "neutral" rating and a $24.00 price target for the company. Piper Sandler initiated coverage on Kestra Medical Technologies in a research note on Monday. They set an "overweight" rating and a $27.00 price objective for the company. Wolfe Research started coverage on Kestra Medical Technologies in a report on Monday. They set an "outperform" rating and a $29.00 target price for the company. Finally, Wells Fargo & Company initiated coverage on Kestra Medical Technologies in a research note on Monday. They issued an "overweight" rating and a $28.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $27.67.
View Our Latest Analysis on KMTS
Kestra Medical Technologies Stock Down 3.0 %
NASDAQ KMTS traded down $0.73 during trading hours on Monday, reaching $23.29. The company's stock had a trading volume of 62,011 shares, compared to its average volume of 275,704. Kestra Medical Technologies has a 1-year low of $20.00 and a 1-year high of $26.06.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
